By Stephen Nakrosis
Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for certain types of carcinoma.
Opdivo, or nivolumab, plus Yervoy, or ipilimumab, was approved as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma, the company said Friday. HCC is the most common primary liver cancer, according to the company.
The company also said Phase 3 trial results showed Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to the investigator's choice of lenvatinib or sorafenib.
The combination treatment received accelerated approval from the FDA in 2020 and has been an established second-line treatment for patients with advanced HCC who were previously treated with sorafenib.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 11, 2025 16:33 ET (20:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。